Bli medlem
Bli medlem

Du är här


MorphoSys AG: MorphoSys Publishes Update on MOR202 in Multiple Myeloma at 15th International Myeloma Workshop

MorphoSys AG / MorphoSys Publishes Update on MOR202 in Multiple Myeloma at
15th InternationalMyeloma Workshop . Processed and transmitted by NASDAQ OMX
Corporate Solutions.The issuer is solely responsible for the content of this
First Data from Final 16 mg/kg Dose Escalation Cohort and Combination with
Immunomodulatory Drugs Show Encouraging Activity

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
published updated safety and preliminary efficacy data on its proprietary
drug candidate MOR202 from an ongoing phase 1/2a study. MOR202 is a fully
human HuCAL antibody targeting CD38, a highly expressed and validated target
in multiple myeloma. The clinical data, which will be presented at the 15th
International Myeloma Workshop in Rome, Italy, September 23th-26th, confirm
the very good overall safety profile previously reported at this year's ASCO
meeting. The update also includes promising first results from the highest
dose escalation cohort of 16 mg/kg of MOR202 weekly plus dexamethasone and
from the recently initiated combination arms with the immunomodulatory drugs
(IMiDs) pomalidomide and lenalidomide.

As of August 24, 2015, 50 heavily pretreated patients with relapsed/refractory
multiple myeloma had received MOR202 with and without dexamethasone and in a
few cases in combination with pomalidomide or lenalidomide as part of a
recently initiated second part of the study. MOR202 continued to demonstrate
long-lasting tumor control, as well as signs of activity. In addition to the
earlier reported very good partial response (VGPR) in a cohort dosed weekly
with 4 mg/kg of MOR202 plus dexamethasone, a minor response (MR) in the 8
mg/kg MOR202 weekly plus dexamethasone cohort further improved into a partial
response (PR). A first MR was observed in one patient in an ongoing cohort at
the highest dose level, of 16 mg/kg MOR202 plus dexamethasone. The first
evaluable patient in the ongoing combination cohort of 8 mg/kg MOR202 plus
pomalidomide and dexamethasone achieved a PR already after the first cycle.
In the ongoing combination cohort of 8 mg/kg MOR202 plus lenalidomide and
dexamethasone, one patient showed a MR after the first cycle. In total, the
data shows one VGPR, two PRs and two MRs so far.

"The MOR202 data have matured nicely since we presented the program at this
year's ASCO conference and we expect an even more comprehensive picture as
the trial progresses. First results from the combination cohorts with
lenalidomide and pomalidomide confirm the synergistic potential we have
demonstrated in preclinical studies using our antibody together with these
two IMiDs. This bodes well for the future development of MOR202," commented
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.

The data to be presented at the International Myeloma Workshop 2015 show that
MOR202 was safe and tolerable and could be administered as a 2-hour infusion.
Infusion-related reactions occurred in 15 patients (30%). Only one out of
these 15 patients received dexamethasone as co-medication and experienced an
infusion-related reaction (grade 1). In the absence of dexamethasone, all
infusion reactions were grade 1-2 except for one patient with grade 3, mainly
limited to the first infusion. The maximum tolerated dose has not been

"The antibody continues to show a balanced safety and tolerability profile and
the preliminary efficacy seen so far with MOR202 as single agent and in
combinations is promising. Considering the low rate of infusion reactions,
even in cohorts without dexamethasone, the short infusion time and other
aspects, MOR202 may turn out to be an excellent choice in terms of safety and
tolerability," commented Dr. Marc-Steffen Raab, Group Leader Experimental
Therapies for Hematologic Malignancies at the Heidelberg University Hospital
and the German Cancer Research Center DKFZ.

The study is ongoing and MorphoSys plans to provide a further update at a
medical conference later this year.

The IMW poster can be downloaded from the Company's website:

Poster #0156

Raab et al.: A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087)
in relapsed or refractory multiple myeloma

The poster presentation will take place on Friday Sep 25th, 6:40pm to 7:40pm

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®, Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications&IR

Mario Brkulj

Associate Director Corporate Communications&IR

Alexandra Goller

Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

Media Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.